| Authors: |
Bender C; Bayer AG, Pharmaceuticals, Research & Development, Building 0520, 42096 Wuppertal, Germany. Electronic address: christian.bender@bayer.com., Eichling S; AbbVie Deutschland GmbH & Co. KG, NBE Advanced Formulation Development, Building 11, 67061 Ludwigshafen, Germany., Franzen L; Bayer AG, Pharmaceuticals, Research & Development, Building 0226, 23096, 42096 Wuppertal, Germany., Herzog V; AbbVie Deutschland GmbH & Co. KG, NBE Advanced Formulation Development, Building 11, 67061 Ludwigshafen, Germany., Ickenstein LM; Boehringer Ingelheim Pharma GmbH & Co. KG, Pharmaceutical Development Biologicals, Building G55, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany., Jere D; Drug Product Services, Lonza AG, Hochbergerstrasse 60G, CH-4057 Basel, Switzerland., Nonis L; Drug Product Services, Lonza AG, Hochbergerstrasse 60G, CH-4057 Basel, Switzerland., Schwach G; F.Hoffmann-La Roche Ltd., Pharmaceutical Development and Supplies Europe Biologics, Grenzacherstrasse 124, 4070 Basel, Switzerland., Stoll P; Boehringer Ingelheim Pharma GmbH & Co. KG, Pharmaceutical Development Biologicals, Building G55, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany., Venczel M; Sanofi-Aventis Deutschland, Global CMC Development, Industriepark Hoechst, Building H770, 65926 Frankfurt am Main, Germany., Zenk S; Sanofi-Aventis Deutschland, Global CMC Development, Industriepark Hoechst, Building H770, 65926 Frankfurt am Main, Germany. |